siRNA抗HBV感染领域中的化学修饰和体内传递研究进展  

Research Progress of siRNA Chemical Modification and Delivery in Vivo for Anti-infective Therapy of Hepatitis B Virus Infection

作　　者：张相宜[1] 柳琳[1] 张幸国[1] 谢方舟[2] 

机构地区：[1]浙江大学医学院附属第一医院药剂科,浙江杭州310003 [2]北京服装学院服装工程材料系,北京100029

出　　处：《药品评价》2013年第22期9-13,41,共6页Drug Evaluation

基　　金："葛根素非对映异构体单晶的HPLC-CMPA拆分及不良反应研究"。浙江省中医药管理局项目;编号:2010ZA063;"几种新型乌药生物碱的抗炎作用及机制研究";浙江省中医药管理局项目。编号:2011ZB063;"蒲黄总黄酮对肾小球系膜细胞增殖的影响及机制研究";浙江省药学会医院药学专项科研基金项目;编号:2012ZYY01

摘　　要：世界人口中约有3.5亿感染乙肝病毒,乙肝病毒感染是急慢性肝炎的主要原因,其与肝纤维化和肝细胞癌的发生密切相关。目前的治疗药物不良反应多或易产生耐药性,因此迫切需要找到新的治疗手段。本文依据近5年来国内外文献进行分析、归纳、总结,综述了治疗HBV感染的小干扰RNA(small RNA interference,siRNA)药物在化学修饰和体内传递方面新进展。RNAi途径可实现病毒基因转录后沉默,特异性和有效性地抑制HBV基因的表达和复制,是治疗HBV感染的一种新颖而有效的途径。而小干扰RNA(siRNA)的化学修饰和体内传递研究,可提高其在体内的稳定性和靶向性。Approximately 350 million of the world＇s population have hepatitis B virus infection, which is a major cause of acute and chronic hepatitis, and carriers of the virus are at risk for hepatocellular carcinoma and cirrhosis. Current treatment regimens, such as interferon-or and nueleotide analogues are only partially effective and new treatment methods remain an important goal. According to the studies at home and abroad of recent five years, new progress in chemical modification and delivery in vivo of small RNA interference （siRNA） treatment for HBV infection was reviewed. RNAi pathway can induce post-transcriptional gene silencing. The specific and potent suppression of HBV gene expression and replication is a novel and effective way for the treatment of HBV infection. Chemical modification and delivery in vivo study can increase stability and improve targeted delivery.

关 键 词：RNA干扰 乙肝病毒 小干扰RNA 化学修饰 体内递送 

分 类 号：R91[医药卫生—药学]